Sam Finkel

Sam Finkel has been in the biomedical engineering field since 2017. Sam began their career as an R&D Intern at CartiHeal, where they conducted quality assurance tests on the aragonite material used for Agili-C implants and assisted in the manufacturing of the implants. In 2018, they worked as an Undergraduate Research Assistant in the Levenberg Lab at Technion International- Israel Institute of Technology, where they performed cell cultures and prepared bone samples for histological staining. In 2019, they were an R&D Summer Intern at AstraZeneca, where they developed a CRISPR-mediated strategy to knockout YAP1 gene in iPSCs. In the same year, they were a Business Development Consultant at Neshima Medical LTD. Currently, they are an Engineering Lead, Cardiac and a Biomedical Engineer at FluidForm.

Sam Finkel attended The Frisch School from 2011 to 2015. In 2016, they began their Bachelor of Science (BS) in Bioengineering at the University of Maryland, and in 2018 they studied at the Technion - Israel Institute of Technology. Sam completed their Bachelor of Science in Bioengineering at the University of Maryland in 2020.